The options market is flashing elevated volatility for CAVA Group as the company approaches its earnings announcement. One-month implied volatility has climbed to 76.54%, a rise of 2.2 percentage points that places the metric in the 89th percentile. Shares are trading around $63.05 as traders brace for a sizable move; the market is currently pricing about an 11% swing around the upcoming earnings event (Aug 11).
Options market: elevated hedging and speculative interest
The skew, a measure of the relative demand for out-of-the-money calls versus puts, recorded a sharp increase of 12.51 points—a move described as a 3.8 standard deviation event within the context provided. That jump indicates an unusually strong shift in what option buyers are paying for calls versus puts and suggests significant appetite for positioning ahead of the report. Activity is split: heavy put flows have shown up at the $65 strike for both Dec 2026 and Mar 2027 expirations, while call interest appears concentrated at the $70 strike for Aug 2026.
Market participants have historically seen larger-than-expected moves around CAVA earnings in some instances: the stock has moved more than the options-implied swing in 5 of the last 8 reports, underscoring that implied moves can sometimes understate realized volatility.
Valuation and fundamentals: growth narrative priced at a premium
On fundamental metrics, CAVA appears priced for continued rapid results. Trailing price-to-earnings sits at 51.2x, and the forward P/E rises to 110.5x, reflecting market expectations for significant earnings growth ahead. Revenue growth is estimated at 22.4% for fiscal 2025 with a forecast of 27.1% for fiscal 2026. Earnings-per-share for FY2025 show a decline of 51.7%, which the data attributes to investment and expansion costs.
Analytic valuations place a fair value estimate at $64.37, which is close to the prevailing share price. By contrast, the mean analyst target is $91.29, implying roughly 21.2% upside from current levels. Return on equity and return on invested capital are modest at 8.6% and 4.4% respectively. The company does not pay a dividend and continues to reinvest earnings into growth initiatives.
Brokerage coverage cited includes Telsey, which maintains an Outperform rating with a $95 target and describes CAVA’s growth targets as "conservative," and RBC Capital, which also carries an Outperform rating and a $90 target while noting recent share-price weakness.
Short-term market picture and headline risk
Realized volatility for the stock is 50.7%, highlighting the security's historical price fluctuation. Recent sector headlines have added to pressure: a FDA cyclosporiasis outbreak is reported to have hit the sector, with Sweetgreen cited as hardest hit; CAVA has experienced a 24.52% decline over the last month in the context described. Technically, short-term momentum readings are negative, with most hourly and daily indicators categorized as "sell" or "strong sell."
Bottom line - a meaningful move looks likely, direction uncertain
Given the elevated implied volatility, pronounced skew shift, and concentrated activity in both puts and calls, the options market is signaling that traders expect a notable price reaction to the earnings release. Because demand is present on both sides of the market, the prevailing conclusion is that a sizable move is likely but the direction remains unclear. A beat with positive guidance could push the stock toward analyst targets, while disappointing results or signs of margin pressure could lead to renewed weakness and a test of recent lows. This profile represents a high-expectation, high-risk earnings setup.